Skip to main content

Table 1 Descriptive data and outcome of COVID-19

From: Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset

Descriptive Statistics

N = 335(%)

Age in years (mean±SD)

48.62 ± 12.07

Gender M(F)

65 (270)

Duration of AIRD in months

Less than 24 Months

60 (17.91%)

Greater than or Equal to 24 Months

275 (82.09%)

Smoking History

5 (1.49%)

DM

43 (12.84%)

HTN

71 (21.19%)

Obesity BMI > 30

11 (3.28%)

Asthma/ILD

9 (2.69%)

Diagnosis

RA

246 (73.43%)

PsA

29 (8.66%)

SpA

35 (10.45%)

Others

25 (7.46%)

COVID-19 Infected Patients

(N = 36)

Hospitalization

10 (27.78%)

O2 therapy

7 (19.44%)

ICU admission

3 (8.33%)

Mortality (Death)

3 (8.33%)

  1. AIRD: Autoimmune Rheumatic Diseases; DM: Diabetes Mellitus, HTN: Hypertension, BMI- Body Mass Index, ILD: Interstitial lung disease, RA: Rheumatoid Arthritis; PsA: Psoriatic Arthritis; SpA- Spondyloarthritis; ICU: Intensive care unit